Skip to main content
. 2014 Feb 3;111(7):2482–2487. doi: 10.1073/pnas.1400283111

Table 2.

Expression of globo-series GSLs in cancer cell lines

Tumor origin SSEA-4+ SSEA-3+ Globo H+ SSEA4+ or SSEA3+ or Globo H+ SSEA-4+ SSEA-3+ SSEA-4+ Globo H+ SSEA-4+ SSEA-3+ Globo H+
Brain 12/17 9/17 6/17 12/17 9/17 6/17 5/17
Lung 13/20 5/20 13/20 16/20 5/20 10/20 5/20
Breast 17/23 6/23 14/23 18/23 6/23 13/23 6/23
Mouth 8/13 2/13 11/13 12/13 2/13 7/13 2/13
Esophagus 1/2 0/2 2/2 2/2 0/2 1/2 0/2
Stomach 4/6 3/6 6/6 6/6 3/6 4/6 3/6
Liver 6/10 4/10 9/10 9/10 4/10 6/10 4/10
Bile duct 2/5 1/5 3/5 3/5 1/5 2/5 1/5
Pancreas 8/8 3/8 6/8 8/8 3/8 6/8 3/8
Colon 5/7 0/7 6/7 7/7 0/7 4/7 0/7
Kidney 5/6 0/6 5/6 6/6 0/6 4/6 0/6
Cervix 3/4 2/4 1/4 3/4 2/4 1/4 0/4
Ovary 8/9 2/9 5/9 8/9 2/9 5/9 2/9
Prostate 4/4 1/4 1/4 4/4 1/4 1/4 0/4

Expression of globo-series GSLs was determined by flow cytometry. Cell lines in which more than 15% of total cells were positive in flow cytometry are labeled positive.